OVID-19 tests to sons: how well know UK NEQAS?


PPi Editor Andy Myall andymyall@stepcomms.com


Science Editor Brian Nation CSci FIBMS briannation@stepcomms.com


Publisher Geoff King geoffking@stepcomms.com


Journal Administration Katy Cockle katycockle@stepcomms.com


Advertisement Sales sales@pathologyinpractice.com


Design Laurence Hallam


ident Elect of UK NEQAS and Dina Patel, Scientific Director ogy, Immunochemistry and Allergy offer a look inside UK s in practice. They share real-world examples to demonstrate how the organisation delivers exceptional value to clinical


Publishing Director Trevor Moon trevormoon@stepcomms.com


Pathology in Practice may not be reproduced in any way without prior written consent of the publisher.


rs. e a


ng ust


ned


ght 043


ently.


Step House, North Farm Road Tunbridge Wells Kent TN2 3DR Tel: 01892 779999


Email: info@pathologyinpractice.com ISSN 1465-9131


Register your details to receive free copies of the magazine. SCAN HERE


UKHSA, to set up a viable COVID-19 antigen scheme. As an organisation, UK NEQAS created a number of pragmatic EQA programmes that monitored both the testing kits and the interpretation of the results within a fast-paced laboratory


QAS e UK


ARTICLES


www.pathologyinpractice.com | www.ukneqas.org.uk EXTERNAL QUALITY ASSESSMENT


How innovation and science drive the development of EQA


Why UK NEQAS d what it does: it’s a the patients


CONTENTS 3


Why UK NEQAS is here – education, education, education!


Why UK NEQAS does what it does: it’s all about the patients


From COVID-19 tests to free lessons: how well do you know UK NEQAS?


The challenges of creating an EQA scheme for digital pathology


UK NEQAS: delivering far more than external quality assessment


testing setting being demanded by scientists, health professionals and the public during a global pandemic. Everyone across UK NEQAS came together to share knowledge and support.”


Everything that UK NEQAS does is for the benefit of patients. All the impartial advice delivered, the challenging samples sent to laboratories, the webinars and conferences hosted, and the data shared – everything is done to try to improve the potential outcomes of the patients.


Dr Deborah Pritchard and Dr Gwen Wark, members of the UK NEQAS Board, explain how UK NEQAS gives users the confidence that they are providing the best results for their assays, and clinical teams and patients the reassurance that they are receiving the correct informatio to manage health conditions and treatment.


6 9 12


With 70% of diagnoses relying on pathology results, patients are the reaso why EQA exists and why it’s imperative that we always keep them in mind when delivering EQA. These are real people, going through a very challenging time in their lives, and despite us not being


15 19


acted t a


s for est


m in


D-19 on,


g UK n


At the start of the COVID-19 pandemic, UK NEQAS worked quickly to determine the relevant EQA for the national scale antibody and antigen testing regime.


2 AUGUST 2024


With 8,000 biochemistry samples analysed on average, every day in just one hospital – thousands of patients are relying on the outcome of laboratory tests, putting the importance of EQA into sharp focus.


2024 WWW.PATHOLOGYINPRACTICE.COM 31


PATHOLOGY IN PRACTICE


Stimmungsbilder1 / stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21